Sanofi completes acquisition of Protein Sciences

PARIS — Sanofi announced Monday that it has completed the acquisition of Protein Sciences, a vaccines biotechnology company based in Meriden, Conn. This completion follows Federal Trade Commission approval, having met all the conditions required for the closing of the transaction.



Through the acquisition, Sanofi Pasteur, the vaccines global business unit of Sanofi, adds a promising product to its influenza vaccine portfolio: Flublok (Influenza Vaccine), the only recombinant protein-based influenza vaccine approved by the U.S. Food and Drug Administration.



“We are thrilled to welcome the talented employees and assets of Protein Sciences within Sanofi Pasteur,” stated David Loew, Sanofi EVP and head of Sanofi Pasteur. “The addition of Flublok Quadrivalent vaccine represents a very attractive opportunity to complement our influenza vaccines portfolio.”



The acquisition of Protein Sciences fits with Sanofi Pasteur’s strategic initiative to explore non-egg-based influenza vaccine manufacturing technologies. “This acquisition is consistent with our strategic ambition of expanding our presence in the respiratory vaccine market, and builds on the recently announced collaboration on an investigational respiratory syncytial virus monoclonal antibody,”  Loew added.